Drug Registration in Thailand
: Regulatory Overview
Thailand has become one of Southeast Asia's most attractive healthcare markets, supported by a well-established regulatory framework, strong healthcare infrastructure, and increasing demand for innovative pharmaceutical and medical device products. However, navigating Thai regulatory requirements requires careful planning, technical expertise, and a thorough understanding of the Thai Food and Drug Administration (Thai FDA).
1. Product Classification
Determining the correct regulatory pathway is the first and most important step. Products may be classified as:
New Drugs
Generic
Drugs Longer
New Generic Drugs
Biological Products
Biosimilars
Traditional Medicines
Herbal Medicinal Products
Different product categories require different levels of supporting evidence and review timelines.
2. Regulatory Strategy
Before dossier preparation, sponsors should assess:
Product eligibility
Registration category
Bridging study requirements
Bioequivalence (BE) study requirements
Clinical data requirements
Reference products
Local regulatory expectations
A well-planned regulatory strategy often shortens overall approval time.
3. Dossier Preparation
Thailand follows the ICH CTD format for pharmaceutical registration.
The submission generally includes:
CTD Modules
Module 1 – Regional Administrative Information
Region-specific (e.g., Thai FDA forms, local labeling, application forms).
Module 2 – Summaries
Quality Overall Summary
Nonclinical Overview & Summary
Clinical Overview & Summary
Provides concise, high-level summaries of Modules 3–5.
Module 3 – Quality
Chemistry, Manufacturing, and Controls (CMC).
Includes specifications, analytical methods, stability data, and manufacturing processes.
Module 4 – Nonclinical Study Reports
Pharmacology studies
Pharmacokinetics (PK) studies
Toxicology studies
Module 5 – Clinical Study Reports
Clinical trial data (efficacy and safety)
Clinical pharmacology studies
Integrated summaries of effectiveness and safety
Bioequivalence
study reports
Risk management information
Labeling and package inserts
All documents must comply with current Thai FDA requirements.
4. Thai FDA Review
Following submission, the authority performs:
Administrative review
Technical assessment
Quality evaluation
GMP verification
Clinical evaluation
(when applicable)
Deficiency queries (if necessary)
Local regulatory expectations
Applicants must respond promptly to regulatory questions to prevent review delays.
5. Marketing Authorization
Once approved, the product receives a registration license permitting commercial distribution in Thailand.
Sponsors must also comply with post-marketing obligations, including:
Variation applications
License renewal
Pharmacovigilance
Safety reporting
Label updates
GMP compliance
Applicants must respond promptly to regulatory questions to prevent review delays.
Bioequivalence (BE)
Studies in Thailand
Many generic pharmaceutical products require bioequivalence studies before registration.
Thai FDA generally requires BE studies to demonstrate therapeutic equivalence between
the generic product and the reference product.
For many products intended for the Thai market, local BE studies conducted at qualified Thai research
centers are expected. Foreign BE studies may be accepted under certain circumstances, such as oncology products or specific first-generic situations, subject to Thai FDA requirements and scientific justification.
Selecting an appropriate BE strategy early in development can significantly reduce registration risks.